Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
about
Axitinib in the treatment of renal cell carcinoma: patient selection and perspectivesSequence of treatment in locally advanced and metastatic renal cell carcinomaA survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activitiesEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaA phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II studyImmunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysisAngiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Axitinib for the treatment of advanced renal cell carcinoma.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The circadian timing system in clinical oncology.Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.Axitinib plasma pharmacokinetics and ethnic differences.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Axitinib in metastatic renal cell carcinoma.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Axitinib: a review in advanced renal cell carcinoma.Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Axitinib for the treatment of metastatic renal cell carcinoma.Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.
P2860
Q26751341-32B7EE46-D117-4A4E-A5AD-052071CD7DB4Q26773653-01813EF0-3718-477E-BC06-0C06AED75AC3Q26774752-23078EB5-D734-456A-A75F-801E01100373Q27028048-A04AD4C8-855C-4344-AB56-A0C92AEF936AQ28066747-22CDDE65-5A99-4AEC-8250-D2B98C893725Q33419633-35B5CE4C-8EF1-4CE4-AAF8-089042CAD041Q33633424-AB64F8FD-C697-40E8-A0C4-89ED7CBAF03AQ33823247-7D919ED7-35AF-4824-918E-C044FB58684AQ34660154-1F29B140-4AD2-4F48-9A64-1458A2DE043CQ34661185-62998377-D0DE-4FA1-A076-D5D181CF5665Q35079536-34CA320F-E533-48D4-B335-3CE69B218E27Q35413876-46ACA5F4-0095-481F-B105-EB16A4EB90F3Q35562209-8DEB7E98-6613-49C8-A487-3ADA2EFED1CCQ35758408-D80B75D2-96AA-4063-B3CC-D39FBD7D9FA6Q36051199-35C29618-8D12-4814-96FE-8A1293BA6C6AQ37387563-972CEC56-7A37-4667-A5B0-E1615FFFD1ECQ38170397-0FEB13E0-075D-4454-A4C6-84853DC1E265Q38190857-B3033C36-FF5F-4A66-AEFC-C18A9152B60BQ38196855-52107F1D-65B3-476E-A75B-30A0DC715F38Q38201503-A265EA4F-B38F-4D14-8425-7056804BBE08Q38219193-6471B416-81AD-4859-ABF5-C254105F52C2Q38335105-D6482790-7A91-46C3-82AA-7D9716A1D4C5Q38348548-FC4FCFB2-A646-431D-913A-6D9C70FCEE6AQ38378485-CD1A4891-A3DB-4A1F-B422-D21E2471FA39Q38439661-26447B27-16C0-4401-965A-E7985BFAE238Q38514440-101AE442-BFD3-4689-BDF5-3766D8F54123Q38612808-518D7E18-4BDA-4F5D-95D0-2396575D7AEDQ38628043-37E10D0A-3925-4B6B-BA5D-8119C2FEBA0CQ38655156-E83D2FD1-40A3-4A90-B771-CD5ED77A8B5FQ38657787-277FC220-8D9C-4A13-8182-BC3472A2DAFDQ38673512-C81FAB04-D3B2-45E9-BEFC-1F7E273272BEQ38697227-87EF3C8A-D363-4E89-812D-66CD56C0AA77Q38836780-C05EE542-4D74-4660-95AD-6D7017C7520EQ38975599-0312B75E-C8A9-4A15-B47F-EA9B6335FEE4Q39044249-8E3BEFBE-3B95-4A89-94E6-58ACE660D1ECQ39095194-DF71B085-64E1-4A9B-8A84-D6E200727605Q39100001-EE90BD34-E52D-4A15-8CBF-FE96447A4403Q39219788-A7182B45-B91C-47C9-97E3-E557C42D2734Q39429946-DCC65656-880F-41B0-BEC5-7A9BFBC523BDQ40109938-FF3E619D-F1CA-4F30-A613-C7D23D949D88
P2860
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Axitinib with or without dose ...... sed double-blind phase 2 trial
@ast
Axitinib with or without dose ...... sed double-blind phase 2 trial
@en
type
label
Axitinib with or without dose ...... sed double-blind phase 2 trial
@ast
Axitinib with or without dose ...... sed double-blind phase 2 trial
@en
prefLabel
Axitinib with or without dose ...... sed double-blind phase 2 trial
@ast
Axitinib with or without dose ...... sed double-blind phase 2 trial
@en
P2093
P2860
P1433
P1476
Axitinib with or without dose ...... sed double-blind phase 2 trial
@en
P2093
Angel H Bair
Bohuslav Melichar
Brian I Rini
Dmitri Pavlov
Eric Jonasch
Glen I Andrews
José A Arranz
Mayer N Fishman
Takeshi Ueda
P2860
P304
P356
10.1016/S1470-2045(13)70464-9
P577
2013-10-18T00:00:00Z